» Articles » PMID: 29277839

Effect of Synbiotic Supplementation in Children and Adolescents with Cystic Fibrosis: a Randomized Controlled Clinical Trial

Abstract

Background/objectives: Cystic fibrosis (CF) is characterized by excessive activation of immune processes. The aim of this study was to evaluate the effect of synbiotic supplementation on the inflammatory response in children/adolescents with CF.

Subjects/methods: A randomized, placebo-controlled, double-blind, clinical-trial was conducted with control group (CG, n = 17), placebo-CF-group (PCFG, n = 19), synbiotic CF-group (SCFG, n = 22), PCFG negative (n = 8) and positive (n = 11) bacteriology, and SCFG negative (n = 12) and positive (n = 10) bacteriology. Markers of lung function (FEV), nutritional status [body mass index-for age (BMI/A), height-for-age (H/A), weight-for-age (W/A), upper-arm fat area (UFA), upper-arm muscle area (UMA), body fat (%BF)], and inflammation [interleukin (IL)-12, tumor necrosis factor-alpha (TNF-α), IL-10, IL-6, IL-1β, IL-8, myeloperoxidase (MPO), nitric oxide metabolites (NOx)] were evaluated before and after 90-day of supplementation with a synbiotic.

Results: No significance difference was found between the baseline and end evaluations of FEV and nutricional status markers. A significant interaction (time vs. group) was found for IL-12 (p = 0.010) and myeloperoxidase (p = 0.036) between PCFG and SCFG, however, the difference was not maintained after assessing the groups individually. NOx diminished significantly after supplementation in the SCFG (p = 0.030). In the SCFG with positive bacteriology, reductions were found in IL-6 (p = 0.033) and IL-8 (p = 0.009) after supplementation.

Conclusions: Synbiotic supplementation shown promise at diminishing the pro-inflammatory markers IL-6, IL-8 in the SCFG with positive bacteriology and NOx in the SCFG in children/adolescents with CF.

Citing Articles

Effect of Pre-, Pro-, and Synbiotics on Biomarkers of Systemic Inflammation in Children: A Scoping Review.

Momo Kadia B, Allen S Nutrients. 2024; 16(3).

PMID: 38337621 PMC: 10856957. DOI: 10.3390/nu16030336.


Positioning the preventive potential of microbiome treatments for cystic fibrosis in the context of current therapies.

Cauwenberghs E, De Boeck I, Spacova I, Van Tente I, Bastiaenssen J, Lammertyn E Cell Rep Med. 2024; 5(1):101371.

PMID: 38232705 PMC: 10829789. DOI: 10.1016/j.xcrm.2023.101371.


Prebiotics for people with cystic fibrosis.

Williams N, Jayaratnasingam J, Prayle A, Nevitt S, Smyth A Cochrane Database Syst Rev. 2023; 9:CD015236.

PMID: 37753791 PMC: 10523429. DOI: 10.1002/14651858.CD015236.pub2.


Probiotics Administration in Cystic Fibrosis: What Is the Evidence?.

Esposito S, Testa I, Mariotti Zani E, Cunico D, Torelli L, Grandinetti R Nutrients. 2022; 14(15).

PMID: 35956335 PMC: 9370594. DOI: 10.3390/nu14153160.


Lung-Directed Bacteriotherapy in Cystic Fibrosis: Could It Be an Option?.

Batoni G, Maisetta G, Kaya E, Esin S Antibiotics (Basel). 2022; 11(3).

PMID: 35326789 PMC: 8944708. DOI: 10.3390/antibiotics11030326.